Literature DB >> 12441938

Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions.

Dipen J Parekh1, Travis Clark, Jeffrey O'Connor, Charlie Jung, Sam S Chang, Michael Cookson, Joseph A Smith.   

Abstract

PURPOSE: A significant number of patients requiring radical cystectomy for bladder cancer have substantial co-morbidity. Nonetheless, these patients often prefer orthotopic neobladder reconstruction to avoid an abdominal stoma. We performed a retrospective study to determine perioperative morbidity in this group of patients.
MATERIALS AND METHODS: We used the American Society of Anesthesiologists physical status classification to assign perioperative risk. Of 250 patients undergoing orthotopic neobladder reconstruction after radical cystectomy during a 5-year period we identified 84 with an American Society of Anesthesiologists score of 3 or greater. Charts were available for review for all patients and none was lost to followup.
RESULTS: Median operative time (calculated from anesthesia ready time to completion of surgery and application of a dressing) was 256 minutes. In 14 patients (16.6%) transfusion of a median of 2 units of allogeneic blood was required. A total of 79 patients (94%) were transferred directly from the recovery room to the general urology floor without a need for postoperative cardiac monitoring. Median hospital stay was 7 days. One patient (1.1%) died on postopera-tive day 9 of a presumed pulmonary embolus after having been discharged home on postoperative day 6. Minor complications occurred in 16 patients (19%). Only 1 patient required a return to the operating room for endoscopic removal of a retained stent fragment.
CONCLUSIONS: In experienced hands radical cystectomy and orthotopic neobladder can be offered to patients with co-morbid conditions. Expeditious performance of the surgical procedure, minimization of blood loss, restricting the surgical incision to an infraumbilical location, and avoidance of intraoperative complications all contribute to decreasing morbidity and mortality. Although orthotopic reconstruction is more complex than performance of an ileal conduit, there is no apparent increase in perioperative morbidity or mortality. Therefore, orthotopic reconstruction can be offered to patients who want to avoid an abdominal stoma even in the face of significant co-morbid conditions.

Entities:  

Mesh:

Year:  2002        PMID: 12441938     DOI: 10.1097/01.ju.0000035645.96508.42

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Bladder cancer in the elderly.

Authors:  Shahrokh F Shariat; Matthew Milowsky; Michael J Droller
Journal:  Urol Oncol       Date:  2009 Nov-Dec       Impact factor: 3.498

2.  Application of an enhanced recovery pathway for ileostomy closure: a case-control trial with surprising results.

Authors:  J Slieker; M Hübner; V Addor; C Duvoisin; N Demartines; D Hahnloser
Journal:  Tech Coloproctol       Date:  2018-05-03       Impact factor: 3.781

3.  Update on the management of non-muscle invasive bladder cancer.

Authors:  Saad Aldousari; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2010-02       Impact factor: 1.862

4.  [Radical cystectomy and urinary diversion in elderly patients with increased comorbidity].

Authors:  J E Gschwend; R E Hautmann; B G Volkmer
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

5.  [Complications and their management after urinary diversion].

Authors:  S Rogenhofer; S C Müller; T Kälble
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

6.  [Cystectomy for indications other than bladder cancer].

Authors:  S Hautmann; K-H Felix-Chun; E Currlin; M G Friedrich; J Dose Schwarz; T Langwieler; S Conrad; H Huland
Journal:  Urologe A       Date:  2004-02       Impact factor: 0.639

Review 7.  Anesthetic challenges of patients with cardiac comorbidities undergoing major urologic surgery.

Authors:  Rudin Domi; Hektor Sula; Ilir Ohri; Arben Beqiri; Myzafer Kaci; Artan Bodeci; Haki Laho
Journal:  Int Arch Med       Date:  2014-04-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.